The Role of Antidepressant Pain Modulators in Managing Esophageal Hypersensitivity and Refractory Gastroesophageal Reflux Disease: A Comprehensive Review
Abstract
The symptoms of esophageal hypersensitivity and refractory gastroesophageal reflux disease (rGERD) become aggressive clinical targets for treatment even when patients have the most effective acid suppression therapy. Science now supports antidepressant pain modulators such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) as potential therapeutic medications because they control esophageal nociceptive signals and central pain signals within the brain. This extensive review examines the functional roles which these treatments perform when treating esophageal hypersensitivity along with rGERD and conducts an assessment of their effectiveness and security data with clinical implications. The review analyzed findings from randomized controlled trials and meta-analyses and observational studies which were published in prestigious journals. The evaluations based on statistics demonstrated how antidepressants as pain modulators perform against standard GERD therapies while assessing symptom control along with life quality benefits and potential side effects in patients. The review examines visceral pain modulation neurophysiology to demonstrate potential treatment approaches for individual patients. Studies reveal that TCA medications together with SSRI medications successfully decrease esophageal pain experiences from central nervous system and peripheral nervous system mechanisms while offering better treatment outcomes to PPI non-responsive…
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.